biotech / news / / MarketScreener
Odyssey Therapeutics has raised $279 million in its upsized U.S. initial public offering.
Odyssey Therapeutics raised $279 million in its upsized U.S. IPO, selling 15.5 million shares at $18 each.
KEY POINTS
- The company’s IPO pricing exceeded its lower range, amid revived biotech listings in 2026.
- Odyssey’s lead drug candidate, OD-001 for ulcerative colitis, is in a mid-stage clinical trial.
- Founder Dr. Gary D. Glick also started Scorpion Therapeutics, acquired by Eli Lilly for $2.5 billion in 2025.
- IPO proceeds will primarily fund OD-001 clinical development and general corporate purposes.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →